Nicerin (Nicergoline)

Nicergoline antagonizes alpha‑1 adrenergic receptors, producing vasodilation of cerebral arteries and increasing blood flow to the brain. It also inhibits platelet aggregation, modulates serotonergic pathways and enhances acetylcholine release, which together support neuronal metabolism and cognitive function in vascular‑related disorders.

The appropriate dose of Nicerin is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, renal and hepatic function, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for nicergoline during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under direct medical supervision.

To request Nicerin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with alternatives such as vinpocetine or cilostazol, nicergoline has a distinct mechanism involving alpha‑1 antagonism and platelet inhibition. Clinical choice depends on the specific vascular profile, tolerability, drug‑interaction potential and physician experience. Nicergoline is often preferred when a combined vasodilatory and antiplatelet effect is desired.

Nicerin tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Nicerin is taken orally, usually with a glass of water. It can be taken with or without food, depending on the prescriber’s advice, and should be swallowed whole; tablets should not be crushed or chewed unless specifically instructed.

The most serious adverse events reported with nicergoline include severe hypotension leading to syncope, cardiac arrhythmias, and hepatic dysfunction. Patients should be monitored for sudden drops in blood pressure, abnormal heart rhythms, or signs of liver injury such as jaundice or elevated liver enzymes.

Nicerin is contraindicated in patients with severe hypotension, recent cerebrovascular accident, active bleeding disorders, or known hypersensitivity to nicergoline or other ergoline derivatives. Caution is also advised for individuals with significant liver disease or those taking interacting medications listed under major interactions.